Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AZD5492 |
Trade Name | |
Synonyms | AZD-5492|AZD 5492 |
Drug Descriptions |
AZD5492 is a trispecific target-induced T-cell activating nanobody targeting CD20 on tumor cells, TCR, and CD8, which potentially induces activation of T-cells and enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
DrugClasses | CD20 Antibody 25 CD3 Antibody 103 |
CAS Registry Number | NA |
NCIT ID | C210037 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AZD5492 | AZD5492 | 0 | 1 |